On Thursday, July 13, 2023, Mark Cuban’s Cost Plus Drug Company announced it is going to offer a 30-day supply of the most recent SGLT-2 inhibitor in the marketplace, Brenzavvy, for treating type 2 diabetes. A 30-day supply will cost $47.85 plus shipping.
Cost Plus Drugs has no membership fees, and insurance just isn’t required to fill a prescription for Brenzavvy at this price.
SGLT-2s are also often known as sodium-glucose cotransporters or gliflozins. This group of oral medications for managing type 2 diabetes is comparatively latest, as canagliflozin (Invokana), one other SGLT-2 medication, was first approved in 2013. SGLT-2s help treat diabetes by reducing renal glucose reabsorption and increasing its urinary elimination, decreasing blood glucose concentrations.
These medications prevent your kidneys from reabsorbing glucose concentrations into your bloodstream and help your body eliminate the surplus through urine.
In keeping with the Endocrinology Network, SGLT-2s lower blood glucose levels in two ways:
- Reducing the quantity of glucose the kidneys absorb to excrete through urine.
- Reducing the quantity of glucose within the bloodstream.
Cost Plus Drugs CEO and co-founder Dr. Alex Oshmyanksy shared that the corporate prioritizes products for individuals with diabetes like SGLT-2s. SGLT-2s are clinically shown to have meaningful advantages for individuals with type 2 diabetes, including reducing the danger of other comorbid conditions.
“Unfortunately, Americans with diabetes have suffered from artificially inflated drug and provide prices for a lot too long,” Dr. Oshmyansky stated. “As a diabetic myself, I’ve experienced this issue first-hand, so adding more products for individuals with diabetes at reasonable prices is a top priority for us.”
With Cost Plus Drugs offering medications like Brenzavvy and Invokana at more cost-effective prices, access to SGLT-2 medicines can improve and positively impact over 30 million Americans living with type 2 diabetes today.